EmeraMed: Targeting the cause of diseases.
Emeramide is a lipophilic compound that crosses the blood-brain barrier and is intracellularly accessible. It is currently under FDA review as a treatment for mercury poisoning.
- COPD: A Phase 2a clinical trial evaluating Emeramide in patients with COPD was completed in 2018. The study found Emeramide to be well-tolerated, with no serious adverse events reported.
- Other conditions: Preclinical studies on Emeramide have been conducted for various other potential applications. Additional clinical research is ongoing or planned.
Latest Information
Seeking Partners in Development
EmeraMed is seeking strategic partners and investors to support the continued clinical development and potential commercialization of Emeramide (also known as NBMI or Irminix®). Emeramide is designed to bind irreversibly to certain heavy metals (such as mercury, arsenic, cadmium, lead, and others) and to address oxidative stress.
The Toxic Journey of Mercury Vapor: Absorption, Oxidation, and Cellular Trapping
How inhaled mercury vapor enters the body, crosses the blood-brain barrier, and becomes trapped in cells — an in-depth look at the mechanisms of mercury vapor toxicity.
Emeramide (NBMI): An Investigational Mercury Chelator
Emeramide (also known as NBMI or Irminix®) is an investigational lipophilic compound in development by EmeraMed. It has not been approved by the FDA for any use.
Warning: Counterfeit Emeramide sold illegally in EU & USA
Counterfeit Emeramide is being sold under our various trade names (OSR#1, NBMI, Emeramide) and tests have shown that it is not Emeramide. This is unsafe and illegal and we are continuously in contact with various regulatory authorities to take action.
Pilot Study Results: Emeramide (NBMI) in Mercury-Exposed Gold Miners in Zaruma Ecuador
In a 2018 randomized, placebo-controlled pilot study of 36 mercury-exposed gold miners in Zaruma, Ecuador, the group taking 300 mg/day of investigational NBMI (Emeramide) showed a statistically significant drop in physical fatigue scores and significantly lower urinary mercury (unadjusted) compared with placebo after 14 days. No serious adverse events were reported. NBMI is not FDA-approved.
Published Research
Important notice: Emeramide (NBMI) is an investigational new drug. Not approved by the U.S. FDA for any use. This material is for scientific information only and does not constitute evidence of safety or efficacy.
What a 2012 Rat Study Found About NBMI After Lethal Mercury Doses
In a 2012 peer-reviewed rat study, every untreated rat given a lethal dose of mercury chloride died, while 16 of 18 rats given a single injection of investigational NBMI (Emeramide) survived the full week, including 4 of 6 at 14 times the lowest lethal dose. The survivors stayed healthy and active through three months of follow-up. Preclinical animal data only; NBMI is not FDA-approved.
How Emeramide (NBMI) Changed Mercury Signaling in Cultured Endothelial Cells
In this 2011 laboratory study, researchers grew mouse blood-vessel lining cells in dishes and exposed them to mercury. The mercury made a cell-signaling process called phospholipase D more active, lowered the cells’ protective glutathione levels, and increased signs of cell stress. When they added Emeramide (also called NBMI) to the same cultures, those mercury-related changes were smaller: PLD activity dropped, glutathione moved back toward normal, and stress markers were lower.
Pilot Study Results: Emeramide (NBMI) in Mercury-Exposed Gold Miners in Zaruma Ecuador
In a 2018 randomized, placebo-controlled pilot study of 36 mercury-exposed gold miners in Zaruma, Ecuador, the group taking 300 mg/day of investigational NBMI (Emeramide) showed a statistically significant drop in physical fatigue scores and significantly lower urinary mercury (unadjusted) compared with placebo after 14 days. No serious adverse events were reported. NBMI is not FDA-approved.
